Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GPC3 CAR-T cells (Shenzhen University General Hospital)
- Development stage
- Unknown
- Lead developer
- Shenzhen University General Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
GPC3 CAR-T cells are an investigational autologous chimeric antigen receptor (CAR) T-cell therapy developed by Shenzhen University General Hospital for the treatment of advanced hepatocellular carcinoma (HCC). The therapy involves genetically modifying a patient's own T cells to express a CAR that specifically targets Glypican-3 (GPC3), a heparan sulfate proteoglycan that is highly overexpressed in liver cancer cells but has minimal expression in healthy adult tissues. By targeting GPC3, the engineered T cells can selectively recognize and eliminate malignant hepatocytes. This cell therapy is currently being evaluated in clinical trials to assess its safety and efficacy in patients with advanced HCC who have progressed after standard treatments.
- Other names
- GPC-3 CAR-T cellsGPC3 CAR-T cellsGPC 3 CAR-T cellsGlypican-3-targeted CAR-T cellsGlypican3-targeted CAR-T cellsGlypican 3-targeted CAR-T cellsGPC3-specific CAR-T cellsGPC-3-specific CAR-T cellsGPC 3-specific CAR-T cells
02
Targets
GPC3 (Glypican-3)
Beyond the preview
Go deeper on GPC3 CAR-T cells (Shenzhen University General Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GPC3 CAR-T cells (Shenzhen University General Hospital).